去甲肾上腺素、血浆肾素活性与收缩性心衰心血管死亡
该研究纳入1477例左室射血分数低于50%的连续心衰门诊患者,随访4.8年,评估神经激素与心血管死亡的关系。结果显示,在调整其他单变量预测因素后,NT-proBNP和血浆肾素活性(PRA)可预测心血管死亡;PRA每翻倍,心血管死亡风险增加8%或7%,并改善重分类与区分度。
要点
- 在收缩性心衰患者中,血浆肾素活性(PRA)独立于NT-proBNP预测心血管死亡。
- PRA每翻倍,心血管死亡风险增加7%–8%,且改善风险重分类与区分度。
- 即使在LVEF<40%的亚组中,PRA仍独立预测结局。
核心结论
- 在LVEF<50%或<40%的心衰患者中,血浆肾素活性(PRA)在包含NT-proBNP的模型中具有独立预后意义,可能成为风险分层的附加工具。
研究设计与样本
- 研究为回顾性队列分析,纳入1999至2016年间在某三级心衰转诊中心就诊的连续心衰门诊患者,LVEF<50%且具备神经激素检测数据。
- 共纳入1477例患者,年龄66±13岁,75%为男性,LVEF中位数32%(IQR 25-38),77%患者LVEF<40%,44%为缺血性心衰。
主要发现
- 中位随访4.8年(IQR 2.4-8.2)期间,376例(26%)死于心血管原因。
- NT-proBNP和PRA在调整所有其他单变量预测因素后仍可预测心血管死亡。
- 在考虑采样时治疗或治疗优化后治疗的两种模型中,PRA每翻倍,心血管死亡风险分别增加8%或7%。
- PRA改善了重分类与区分度指标,并在LVEF<40%亚组中独立预测结局。
关键数值与推荐
- 采样时69%患者使用β受体阻滞剂,75%使用ACE抑制剂/血管紧张素受体拮抗剂,48%使用盐皮质激素受体拮抗剂;治疗优化后分别为88%、87%、66%。
- NT-proBNP、NE、E、PRA和醛固酮的中位数分别为1441 ng/L、494 ng/L、30 ng/L、1.2 ng/mL/小时和130 ng/dL。
临床怎么用
- 对于收缩性心衰患者,可考虑检测血浆肾素活性(PRA)以辅助风险分层,尤其在与NT-proBNP联合评估时。
- PRA的预后价值在LVEF<40%亚组中依然存在,可能有助于识别高危患者。
局限性
- 研究为单中心回顾性队列,结果需在前瞻性研究中验证。
- 神经激素采样时部分患者尚未达到指南推荐的治疗优化状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We analysed the circulating levels and prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP), norepinephrine (NE), epinephrine (E), plasma renin activity (PRA) and aldosterone in patients with systolic heart failure (HF) receiving therapies that target the sympathetic system and the renin-angiotensin-aldosterone axis. METHODS: We retrieved data from consecutive HF outpatients with left ventricular ejection fraction (LVEF) <50% and available neurohormones, evaluated at a tertiary referral centre for HF from 1999 to 2016. RESULTS: Patients (n=1477) were aged 66±13 years, 75% were men, median LVEF was 32% (IQR 25-38), 77% had LVEF <40% and 44% ischaemic HF. At the time of sampling, 69% were on beta-blockers, 75% on ACE inhibitors/angiotensin receptor blockers and 48% on mineralocorticoid receptor antagonists vs 88%, 87% and 66%, respectively, after therapy optimisation. Median NT-proBNP, NE, E, PRA and aldosterone were 1441 ng/L, 494 ng/L, 30 ng/L, 1.2 ng/mL/hour and 130 ng/dL, respectively. Over a 4.8-year follow-up (2.4-8.2), 376 patients died from cardiovascular causes (26%). NT-proBNP and PRA predicted cardiovascular mortality after adjusting for all other univariable predictors. The risk of cardiovascular death increased by 8% or 7% per each doubling of PRA in 2 models considering therapies at the time of sampling or after therapy optimisation. PRA improved metrics of reclassification and discrimination, and independently predicted outcome even in the LVEF <40% subgroup. CONCLUSIONS: In patients with HF with LVEF <50% or <40%, PRA shows independent prognostic significance from a model that includes NT-proBNP, and might represent an additive tool for risk stratification.
引用
- Aimo A, Prontera C, Passino C, et al. Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure. Heart. 2021. PMID: 33712509. doi:10.1136/heartjnl-2020-318791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。